Schneeweiss A, et al. - In the TRYPHAENA study, long-term efficacy and cardiac safety outcomes were reported in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. Observations revealed similar long-term survival outcomes across treatment arms. Total pathological complete response was associated with improved disease-free survival. During long-term follow-up, researchers recognized no new cardiac safety signals.